NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Forecast, Price & News $74.12 +1.36 (+1.87%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$71.81▼$74.3550-Day Range$58.41▼$80.2252-Week Range$20.63▼$82.85Volume618,723 shsAverage Volume778,896 shsMarket Capitalization$3.23 billionP/E RatioN/ADividend YieldN/APrice Target$105.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside42.4% Upside$105.57 Price TargetShort InterestBearish21.95% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.63Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.84) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector311th out of 983 stocksPharmaceutical Preparations Industry139th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $105.57, Axsome Therapeutics has a forecasted upside of 42.4% from its current price of $74.12.Amount of Analyst CoverageAxsome Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.95% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 4.01%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.0 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search Interest37 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.71% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.84) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -19.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -19.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 28.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics (NASDAQ:AXSM) StockAxsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.Read More Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAxsome Therapeutics to Present New Sunosi® Data at SLEEP 2023May 31, 2023 | americanbankingnews.comBrokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $105.57June 3, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 30, 2023 | finance.yahoo.comAxsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 27, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Zacks Research (NASDAQ:AXSM)May 26, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)May 25, 2023 | fool.comAxsome Therapeutics (NASDAQ: AXSM)May 22, 2023 | msn.comAxsome Therapeutics's Return On Capital Employed OverviewJune 3, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 17, 2023 | finance.yahoo.comIs a Victory for Its Rivals Bad News for Axsome Therapeutics?May 17, 2023 | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)May 15, 2023 | msn.comAxsome: Promising Early LaunchMay 14, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Raised to Hold at StockNews.comMay 13, 2023 | finance.yahoo.com3 Growth Stocks to Buy and HoldMay 13, 2023 | finance.yahoo.comAnalysts Just Made A Substantial Upgrade To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) ForecastsMay 13, 2023 | americanbankingnews.comAxsome Therapeutics, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.34) Per Share (NASDAQ:AXSM)May 13, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Issued By William BlairMay 12, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Given New $95.00 Price Target at MizuhoMay 12, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Upgraded to "Hold" at StockNews.comMay 12, 2023 | americanbankingnews.comMorgan Stanley Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $87.00May 11, 2023 | markets.businessinsider.comThis Analyst Creates Bullish Pitch For Axsome Therapeutics On Increased Outlook For Its Depression DrugMay 11, 2023 | americanbankingnews.comGuggenheim Increases Axsome Therapeutics (NASDAQ:AXSM) Price Target to $100.00May 10, 2023 | finance.yahoo.com2 Magnificent Growth Stocks You Can Buy With $150 Right NowMay 10, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Sets New 1-Year High at $82.85May 9, 2023 | finance.yahoo.comAxsome's New Drug Is Scoring a Win. Is the Stock a Buy?May 9, 2023 | seekingalpha.comAxsome Therapeutics: Reviewing Q1 2023 Financials And Pipeline UpdatesMay 9, 2023 | finance.yahoo.comAxsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume RisesSee More Headlines AXSM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Company Calendar Last Earnings5/08/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees108Year FoundedN/APrice Target and Rating Average Stock Price Forecast$105.57 High Stock Price Forecast$200.00 Low Stock Price Forecast$52.00 Forecasted Upside/Downside+42.4%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,130,000.00 Net Margins-109.75% Pretax Margin-107.97% Return on Equity-152.04% Return on Assets-48.29% Debt Debt-to-Equity Ratio1.32 Current Ratio3.02 Quick Ratio2.95 Sales & Book Value Annual Sales$50.04 million Price / Sales64.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book28.84Miscellaneous Outstanding Shares43,570,000Free Float32,898,000Market Cap$3.23 billion OptionableOptionable Beta1.92 Key ExecutivesHerriott TabuteauChairman & Chief Executive OfficerMark L. JacobsonChief Operating OfficerNick PizzieChief Financial OfficerLori EnglebertExecutive VP-Commercial & Business DevelopmentKevin LaliberteExecutive Vice President-Product StrategyKey CompetitorsZai LabNASDAQ:ZLABImmunoGenNASDAQ:IMGNPTC TherapeuticsNASDAQ:PTCTMaravai LifeSciencesNASDAQ:MRVISage TherapeuticsNASDAQ:SAGEView All CompetitorsInstitutional OwnershipMacquarie Group Ltd.Bought 1,498 shares on 6/1/2023Ownership: 0.046%ProShare Advisors LLCSold 926 shares on 5/26/2023Ownership: 0.016%Putnam Investments LLCBought 581 shares on 5/22/2023Ownership: 0.264%Ameriprise Financial Inc.Bought 1,166 shares on 5/22/2023Ownership: 0.016%New York State Common Retirement FundSold 5,073 shares on 5/18/2023Ownership: 0.058%View All Institutional Transactions AXSM Stock - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price forecast for 2023? 13 analysts have issued twelve-month price objectives for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $52.00 to $200.00. On average, they expect the company's stock price to reach $105.57 in the next year. This suggests a possible upside of 42.4% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2023? Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM shares have decreased by 3.9% and is now trading at $74.12. View the best growth stocks for 2023 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.91. The firm had revenue of $94.58 million for the quarter, compared to the consensus estimate of $26.87 million. Axsome Therapeutics had a negative net margin of 109.75% and a negative trailing twelve-month return on equity of 152.04%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (8.68%), BlackRock Inc. (5.67%), BVF Inc. IL (4.89%), FMR LLC (3.13%), State Street Corp (1.83%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $74.12. How much money does Axsome Therapeutics make? Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.23 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. How many employees does Axsome Therapeutics have? The company employs 108 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245. This page (NASDAQ:AXSM) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.